Has Melissa Young, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,390 in general payments to Melissa Young, MD across 645 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Melissa Young, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Melissa Young, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Melissa Young, MD

Endocrinology, Diabetes & Metabolism · Freehold, NJNPI 1831174739

Payments from drug & device makers

$20,390in general payments, 2019–2025

Across 645 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$12K
Novo Nordisk$2K
Lilly USA, LLC$881
AstraZeneca$709
Insulet Corporation$700
Mannkind Corporation$466
plus $4K from 45 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	56	$11,655
Novo Nordisk	151	$1,885
Lilly USA, LLC	65	$881
AstraZeneca(2 entities)	50	$709
Insulet Corporation	9	$700
Mannkind Corporation	42	$466
Boehringer Ingelheim	33	$461
Dexcom, Inc.	19	$387
Amgen(2 entities)	6	$278
Merck	18	$252
Radius Health, Inc.	18	$245
Abbott	14	$229
Antares Pharma, Inc.	13	$187
Xeris Pharmaceuticals, Inc.	13	$174
Amarin Pharma, Inc.	12	$171
Amneal Pharmaceuticals LLC	13	$162
Medtronic(2 entities)	9	$134
AbbVie	10	$128
IBSA Pharma Inc.	10	$123
Johnson & Johnson	7	$91
Pfizer	5	$73
Bayer	5	$70
Eisai Inc.	5	$66
Vivus LLC	4	$58
Valeritas, Inc.	4	$57
Ascensia Diabetes Care US Inc.	4	$53
Companion Medical, Inc.	4	$51
Tandem Diabetes Care, Inc.	4	$48
BD	3	$47
Lifescan, Inc.	3	$42
Shire North American Group Inc	3	$40
Nalpropion Pharmaceuticals LLC	3	$40
Acerus Pharmaceuticals Corporation	3	$38
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$36
Amphastar Pharmaceuticals, Inc.	2	$35
Ultragenyx Pharmaceutical Inc.	2	$33
Clarus Therapeutics Inc.	2	$29
Almatica Pharma LLC	2	$29
Corcept Therapeutics	2	$28
Regeneron Healthcare Solutions, Inc.	2	$28
Zealand Pharma US, Inc.	2	$27
BETA Bionics, Inc.	1	$22
Madrigal Pharmaceuticals	1	$17
Sequel Med Tech, LLC	1	$14
Avvisto Therapeutics, LLC	1	$14
Kyowa Kirin, Inc.	1	$14
Takeda Pharmaceuticals U.S.A., Inc.	1	$13
Aytu Biopharma, Inc.	1	$13
Rhythm Pharmaceuticals, Inc.	1	$13
Cequr Corporation	1	$12
Currax Pharmaceuticals LLC	1	$12

How this compares

$20,390 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$261,629

Medicare patients

621

Services billed

3,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Freehold

Kenneth OrdeneFreehold$109K
Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Taher ModarressiPennington$414K
Navtika DesaiHillsborough$408K
Atara SchultzTeaneck$357K
Anthony CannonTurnersville$296K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →